Health Triage
Health Triage develops AI-based medical devices that support clinicians in oncology screening and diagnosis. Its two main products—BreastNegative for automatically identifying negative mammograms and Prostate V-Bio for classifying prostate tumors by Gleason Grade from MRI—are designed to integrate into clinical workflows and reduce radiologist workload. The company's algorithms are trained on large-scale oncological datasets, including collaboration with Cancer Research UK's OPTIMAM mammography database.
- Healthcare Technology
- Medical Devices
- Artificial Intelligence
- Digital Health
- Hardware
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Breast and prostate cancers are frequently detected at advanced stages when treatment options are limited and survival rates decline. Traditional diagnostic workflows depend heavily on manual image interpretation, which is time-consuming, prone to human error, and burdens radiologists and pathologists with significant workloads. This delays diagnosis and constrains the capacity of screening programs to reach broad populations.
Solution
Health Triage creates AI-based medical devices that support clinicians in oncology screening and diagnosis. The company develops proprietary deep learning algorithms that automate parts of the diagnostic process, reducing workload while improving diagnostic quality. Its two main products target breast and prostate cancer: BreastNegative automatically identifies negative mammograms in screening programs, helping prioritize cases needing radiologist review, while Prostate V-Bio classifies prostate tumors by Gleason Grade using MRI data in a non-invasive manner. These tools are designed to integrate into clinical workflows, providing a "second look" that assists—rather than replaces—the clinician's judgment.
Target Audience
Primary customers are radiologists, urologists, and healthcare facilities involved in cancer screening programs, as well as hospital networks seeking to improve diagnostic efficiency and accuracy in oncology.
Features
- BreastNegative: a medical device that automatically identifies negative mammograms in screening programs, helping prioritize cases requiring radiologist review
- Prostate V-Bio: a non-invasive system based on MRI that classifies prostate cancer according to Gleason Grade, supporting active surveillance decisions
- Proprietary deep learning algorithms developed through an interdisciplinary approach integrating clinical, technical, and scientific expertise
- AI models trained on large-scale oncological datasets, including collaboration with Cancer Research UK's OPTIMAM mammography database
- Clinical validation focus with ongoing studies, including the Breast.AI Perspective project involving over 100,000 women across Italian regions